Physician profile
Michael S Rees
NPI 1144270737
$6,256.35
in general payments reported to CMS, 2019-2025
36 companies · $184 in 2025
The $184 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,035 · 2020: $1,003 · 2021: $1,218 · 2022: $1,217 · 2023: $862 · 2024: $738 · 2025: $184.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,784.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,783.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,863.03 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Amgen INC. | $645.57 | 2019-2025 | Evenity, Prolia, Repatha |
| Lilly USA, LLC | $438.39 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals Lp | $357.64 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $344.64 | 2019-2024 | Jardiance |
| Abbvie INC. | $264.33 | 2019-2025 | |
| Abbott Laboratories | $182.41 | 2021-2024 | Octrode, Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $173.21 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $147.40 | 2019-2024 | Capvaxive, Gardasil, Gardasil 9 |
| Janssen Pharmaceuticals, INC | $145.73 | 2019-2022 | |
| Pfizer INC. | $144.60 | 2019-2021 | |
| Amarin Pharma, INC. | $142.45 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $141.24 | 2021-2023 | |
| Kowa Pharmaceuticals America, INC. | $139.80 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $136.32 | 2019-2024 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch Health US, LLC | $123.94 | 2021-2023 | Wellbutrin, Aplenzin |
| Astellas Pharma US INC | $110.25 | 2019-2025 | Veozah |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $101.94 | 2019-2021 | |
| Glaxosmithkline, LLC. | $84.77 | 2020-2025 | Arexvy, Shingrix |
| Medtronic, INC. | $73.29 | 2023-2025 | Intellis Adaptivestim, Vectris Surescan, Inceptiv |
| Ibsa Pharma INC. | $68.08 | 2022 | |
| Esperion Therapeutics, INC. | $60.30 | 2020-2024 | Nexletol |
| Daiichi Sankyo INC. | $52.93 | 2020-2021 | |
| Allergan, INC. | $51.34 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $46.95 | 2019-2021 | |
| Sumitomo Pharma America, INC. | $37.19 | 2023-2024 | Gemtesa |
| Genentech USA, INC. | $34.17 | 2020-2021 | |
| Dexcom, INC. | $19.92 | 2024 | Dexcom G6 Transmitter |
| Biohaven Pharmaceutical Holding Company Ltd. | $19.49 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $19.34 | 2021 | |
| Lundbeck LLC | $17.20 | 2024 | Rexulti |
| Exact Sciences Corporation | $17.04 | 2023 | Cologuard Collection Kit |
| Horizon Therapeutics Plc | $13.96 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $12.97 | 2023 | Evkeeza |
| Seqirus USA INC | $12.77 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $11.75 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Rees listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.